Entering text into the input field will update the search result below

FDA accepts for priority review Bristol Myers's Reblozyl application in beta thalassemia

Beta and alpha thalassemia blood sample

jarun011/iStock via Getty Images

  • Bristol Myers Squibb (NYSE:BMY) announces that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
  • The

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.